Ø iMOS® mannan oligosaccharide competes against pathogenic bacteria for host cell binding sites 

There are many mannose-modified glycoproteins on the surface of human cells. Recent studies have found that pathogenic bacteria, such as Escherichia coli (E.coli), can bind to human cells through the binding of FimH protein at the end of pilus to mannose of glycoprotein. iMOS® mannan oligosaccharide competes for the binding of FimH of E.coli, which abolishes their colonization, thus, it acts as an antibiotic replacement for treatment of infections (Fig.4)

Fig.4 iMOS® mannan oligosaccharide competes against pathogenic bacteria for host cell binding sites

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Spaulding CN et al. 2017.Nature 546:528-532.